SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Lisata Therapeutics, Inc. – ‘10-Q’ for 9/30/22

On:  Thursday, 11/10/22, at 4:12pm ET   ·   For:  9/30/22   ·   Accession #:  320017-22-102   ·   File #:  1-33650

Previous ‘10-Q’:  ‘10-Q’ on 8/4/22 for 6/30/22   ·   Next:  ‘10-Q’ on 5/9/23 for 3/31/23   ·   Latest:  ‘10-Q’ on 11/2/23 for 9/30/23   ·   3 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/10/22  Lisata Therapeutics, Inc.         10-Q        9/30/22   64:6.1M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.27M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     21K 
 3: EX-32       Certification -- §906 - SOA'02                      HTML     20K 
 9: R1          Cover                                               HTML     72K 
10: R2          Consolidated Balance Sheets                         HTML    122K 
11: R3          Consolidated Balance Sheets (Parentheticals)        HTML     39K 
12: R4          Consolidated Statements of Operations               HTML     82K 
13: R5          Consolidated Statements of Comprehensive Loss       HTML     44K 
14: R6          Consolidated Statements of Equity                   HTML    104K 
15: R7          Consolidated Statements of Cash Flows               HTML     90K 
16: R8          The Business                                        HTML     42K 
17: R9          Summary of Significant Accounting Policies          HTML     40K 
18: R10         Merger                                              HTML     30K 
19: R11         Available-for-Sale-Securities                       HTML     58K 
20: R12         Income (Loss) Per Share                             HTML     25K 
21: R13         Fair Value Measurements                             HTML     41K 
22: R14         Accrued Liabilities                                 HTML     27K 
23: R15         Operating Leases                                    HTML     38K 
24: R16         Stockholders' Equity                                HTML     79K 
25: R17         Share-Based Compensation                            HTML     42K 
26: R18         Income Taxes                                        HTML     28K 
27: R19         Australia Research and Development Tax Incentive    HTML     20K 
28: R20         Contingencies                                       HTML     22K 
29: R21         License Agreements                                  HTML     33K 
30: R22         Research Collaboration and License Agreement        HTML     33K 
31: R23         Summary of Significant Accounting Policies          HTML     53K 
                (Policies)                                                       
32: R24         Available-for-Sale-Securities (Tables)              HTML     61K 
33: R25         Income (Loss) Per Share (Tables)                    HTML     25K 
34: R26         Fair Value Measurements (Tables)                    HTML     38K 
35: R27         Accrued Liabilities (Tables)                        HTML     27K 
36: R28         Operating Leases (Tables)                           HTML     39K 
37: R29         Stockholders' Equity (Tables)                       HTML     70K 
38: R30         Share-Based Compensation (Tables)                   HTML     46K 
39: R31         Summary of Significant Accounting Policies          HTML     20K 
                (Details)                                                        
40: R32         Merger (Details)                                    HTML     49K 
41: R33         Available-for-Sale-Securities - Schedule of         HTML     41K 
                Available-for-Sale Securities Reconciliation                     
                (Details)                                                        
42: R34         Available-for-Sale-Securities - Classification of   HTML     25K 
                Available-for-Sale Securities (Details)                          
43: R35         Available-for-Sale-Securities - Available-for-Sale  HTML     34K 
                Securities by Contractual Maturity (Details)                     
44: R36         Income (Loss) Per Share (Details)                   HTML     27K 
45: R37         Fair Value Measurements (Details)                   HTML     31K 
46: R38         Accrued Liabilities (Details)                       HTML     29K 
47: R39         Operating Leases - Narrative (Details)              HTML     24K 
48: R40         Operating Leases - Balance Sheet Presentation       HTML     34K 
                (Details)                                                        
49: R41         Operating Leases - Future Minimum Lease Payments    HTML     33K 
                (Details)                                                        
50: R42         Stockholders' Equity - Equity Issuances (Details)   HTML     47K 
51: R43         Stockholders' Equity - Stock Options and Warrants   HTML    113K 
                (Details)                                                        
52: R44         Stockholders' Equity - Restricted Stock and         HTML     37K 
                Restricted Stock Units (Details)                                 
53: R45         Share-Based Compensation - Share-Based              HTML     29K 
                Compensation Expense (Details)                                   
54: R46         Share-Based Compensation - Compensation Cost Not    HTML     29K 
                Yet Recognized (Details)                                         
55: R47         Share-Based Compensation - Fair Value of Shares     HTML     24K 
                Vested and Weighted Average Estimated Fair Value                 
                of Shares Granted (Details)                                      
56: R48         Income Taxes (Details)                              HTML     41K 
57: R49         Income Taxes (Details)                              HTML     22K 
58: R50         License Agreements (Details)                        HTML     61K 
59: R51         Research Collaboration and License Agreement        HTML     35K 
                (Details)                                                        
62: XML         IDEA XML File -- Filing Summary                      XML    113K 
60: XML         XBRL Instance -- clbs-20220930_htm                   XML   1.27M 
61: EXCEL       IDEA Workbook of Financial Reports                  XLSX    114K 
 5: EX-101.CAL  XBRL Calculations -- clbs-20220930_cal               XML    136K 
 6: EX-101.DEF  XBRL Definitions -- clbs-20220930_def                XML    285K 
 7: EX-101.LAB  XBRL Labels -- clbs-20220930_lab                     XML   1.24M 
 8: EX-101.PRE  XBRL Presentations -- clbs-20220930_pre              XML    664K 
 4: EX-101.SCH  XBRL Schema -- clbs-20220930                         XSD    128K 
63: JSON        XBRL Instance as JSON Data -- MetaLinks              303±   464K 
64: ZIP         XBRL Zipped Folder -- 0000320017-22-000102-xbrl      Zip    509K 




        
Filing Submission 0000320017-22-000102 – SGML Text

Original SGML Text submitted by:  Lisata Therapeutics, Inc. [ formerly Caladrius Biosciences, Inc. ]

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., May 5, 5:28:43.3am ET